Tyra Biosciences to Present Groundbreaking Research at 2026 ASCO GU Symposium
Tyra Biosciences, Inc., a pioneering clinical-stage biotechnology company, has made headlines with its promising advancements in precision medicine. The firm is set to present two impactful poster sessions at the 2026 ASCO Genitourinary (GU) Cancers Symposium, scheduled to take place from February 26 to 28, 2026, in San Francisco, California. This prestigious meeting will be a platform for Tyra to share vital research findings that could significantly influence cancer treatment strategies.
The first poster presentation is titled "ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial." This research, identified by Abstract Number 809, will be presented on February 27, 2026, from 11:30 AM – 12:45 PM PST by Andrew J. Murtha from the University of British Columbia.
In this session, Tyra’s researchers will delve into the effectiveness of ctDNA (circulating tumor DNA) monitoring in patients with FGFR3 alterations undergoing treatment with dabogratinib. Given the growing importance of personalized medicine, this study aims to enhance our understanding of how genetic factors influence treatment response and resistance in urothelial cancer.
The second presentation, "A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302)," bears Abstract Number TPS886. This session will also occur on February 27, 2026, from 11:30 AM – 12:45 PM PST, with Gautam Jayram from Urology Associates in Nashville, TN, as the presenting author.
This phase 2 study seeks to assess both the safety and efficacy of dabogratinib in a specific population of bladder cancer patients, contributing invaluable data to the burgeoning field of FGFR-targeted therapeutics. With a focus on low-grade, non-muscle invasive bladder cancer, the findings from this study are anticipated to influence current best practices and treatment protocols.
Tyra Biosciences’ commitment to transforming oncology through innovative research is further underscored by its proprietary SNÅP platform, which accelerates the drug design process and helps predict genetic mutations related to treatment resistance. Dabo-gra-tinib, Tyra’s lead candidate, exemplifies the company’s dedication to developing targeted therapies that are generally known for their specificity and efficacy. The ongoing studies, including SURF303 and SURF431, are part of Tyra’s ambitious pipeline aimed at addressing significant unmet medical needs in various FGFR-altered cancers.
As the excitement around the upcoming ASCO GU symposium builds, industry leaders and researchers will be eagerly awaiting Tyra's presentations, which promise to provide groundbreaking insights into the future of cancer therapeutics. Attendees are encouraged to visit the ASCO GU website and Tyra’s IR page for further details on the presentations and to follow updates on Tyra’s continued advancements in FGFR-focused therapies. With the potential to reshape treatment landscapes and improve patient outcomes, Tyra Biosciences is undeniably a name to watch in the biotechnology sector.
The first poster presentation is titled "ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial." This research, identified by Abstract Number 809, will be presented on February 27, 2026, from 11:30 AM – 12:45 PM PST by Andrew J. Murtha from the University of British Columbia.
In this session, Tyra’s researchers will delve into the effectiveness of ctDNA (circulating tumor DNA) monitoring in patients with FGFR3 alterations undergoing treatment with dabogratinib. Given the growing importance of personalized medicine, this study aims to enhance our understanding of how genetic factors influence treatment response and resistance in urothelial cancer.
The second presentation, "A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302)," bears Abstract Number TPS886. This session will also occur on February 27, 2026, from 11:30 AM – 12:45 PM PST, with Gautam Jayram from Urology Associates in Nashville, TN, as the presenting author.
This phase 2 study seeks to assess both the safety and efficacy of dabogratinib in a specific population of bladder cancer patients, contributing invaluable data to the burgeoning field of FGFR-targeted therapeutics. With a focus on low-grade, non-muscle invasive bladder cancer, the findings from this study are anticipated to influence current best practices and treatment protocols.
Tyra Biosciences’ commitment to transforming oncology through innovative research is further underscored by its proprietary SNÅP platform, which accelerates the drug design process and helps predict genetic mutations related to treatment resistance. Dabo-gra-tinib, Tyra’s lead candidate, exemplifies the company’s dedication to developing targeted therapies that are generally known for their specificity and efficacy. The ongoing studies, including SURF303 and SURF431, are part of Tyra’s ambitious pipeline aimed at addressing significant unmet medical needs in various FGFR-altered cancers.
As the excitement around the upcoming ASCO GU symposium builds, industry leaders and researchers will be eagerly awaiting Tyra's presentations, which promise to provide groundbreaking insights into the future of cancer therapeutics. Attendees are encouraged to visit the ASCO GU website and Tyra’s IR page for further details on the presentations and to follow updates on Tyra’s continued advancements in FGFR-focused therapies. With the potential to reshape treatment landscapes and improve patient outcomes, Tyra Biosciences is undeniably a name to watch in the biotechnology sector.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.